BRD4 and Carcinoma, Lewis Lung: This was then combinedwith CRV-engineered Lewis lung carcinoma (LLC) cell membranes (CRV-LLCM).The pH/GSH-responsiveness greatly enhanced the release of dBET6 fromthe nanoparticles within the cells, leading to the degradation ofBRD4 in both in vitro and in vivo settings.201 ARV-771 (BRD4 degrader)is encapsulated by a glutathione responsive polymer, leading to ananoengineered BRD4 degrader.